UK markets closed

AgeX Therapeutics, Inc. (AGE)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.5900+0.0150 (+2.61%)
At close: 03:21PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 20.87M
Enterprise value 36.05M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)400.91
Price/book (mrq)12.96
Enterprise value/revenue 680.21
Enterprise value/EBITDA -5.05

Trading information

Stock price history

Beta (5Y monthly) 1.40
52-week change 3-7.26%
S&P500 52-week change 3-15.73%
52-week high 31.3900
52-week low 30.5160
50-day moving average 30.6095
200-day moving average 30.6910

Share statistics

Avg vol (3-month) 324.1k
Avg vol (10-day) 328.36k
Shares outstanding 537.95M
Implied shares outstanding 6N/A
Float 818.45M
% held by insiders 143.49%
% held by institutions 112.67%
Shares short (14 Nov 2022) 4247.18k
Short ratio (14 Nov 2022) 412.88
Short % of float (14 Nov 2022) 41.15%
Short % of shares outstanding (14 Nov 2022) 40.65%
Shares short (prior month 13 Oct 2022) 4312.88k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-13,320.76%

Management effectiveness

Return on assets (ttm)-198.99%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)53k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-62.50%
Gross profit (ttm)125k
EBITDA -6.93M
Net income avi to common (ttm)-9.92M
Diluted EPS (ttm)-0.2450
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)466k
Total cash per share (mrq)0.01
Total debt (mrq)15.65M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.14
Book value per share (mrq)-0.40

Cash flow statement

Operating cash flow (ttm)-6.26M
Levered free cash flow (ttm)-1.97M